Watching closely
$TherapeuticsMD(TXMD.US$ See some improvements in earnings but most importantly why I’ve got my attention here is the following statement from the company! ( said that it is exploring strategic alternatives for the company, which could include a business combination or sale of assets. ) Would love to see a big Pharma swoop in a buy! Thats why it has my attention!![]()
The company also released its Q3 financial report, posting a net loss from continuing operations of $0.13 per share, compared with a net loss from continuing operations of $1.58 per share for the same period in 2022.![]()
The company also released its Q3 financial report, posting a net loss from continuing operations of $0.13 per share, compared with a net loss from continuing operations of $1.58 per share for the same period in 2022.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
